CVS Health names CEO J. David Joyner Board Chair for 2026
CVS Health Corporation announced a governance change at the top of its leadership structure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CVS Health Corporation announced a governance change at the top of its leadership structure. On November 20, 2025, the Board appointed President and Chief Executive Officer J. David Joyner to also serve as Chair of the Board, effective January 1, 2026. After this change takes effect, Michael F. Mahoney will continue as Lead Independent Director, and Roger N. Farah, currently Executive Chair, will remain on the Board as a director. The company also issued a press release describing this appointment, which is filed as an exhibit.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did CVS (CVS) announce in this 8-K filing?
CVS Health Corporation announced that J. David Joyner, its President and Chief Executive Officer, has been appointed to the additional role of Chair of the Board, effective January 1, 2026.
When will J. David Joyner become Chair of the Board at CVS Health?
J. David Joyner will assume the role of Chair of the Board at CVS Health effective January 1, 2026.
What role will Michael F. Mahoney have at CVS after this governance change?
Michael F. Mahoney will continue to serve as the Board’s Lead Independent Director after J. David Joyner becomes Chair of the Board.
What happens to Roger N. Farah’s position at CVS Health after January 1, 2026?
Roger N. Farah, who is currently serving as Executive Chair of the Board, will continue to serve on the Board as a director after the effective date of Joyner’s appointment.
Did CVS Health issue a press release about J. David Joyner’s appointment?
Yes. CVS Health issued a press release announcing the appointment of J. David Joyner as Chair of the Board, which is filed as Exhibit 99.1 to this report.
Which stock exchange lists CVS Health common stock and under what symbol?
CVS Health common stock, par value $0.01 per share, is listed on the New York Stock Exchange under the trading symbol CVS.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
Registrant’s Telephone Number, Including Area Code
N/A
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01. | Other Events. |
Appointment of J. David Joyner as Chair of the Board of Directors
On November 20, 2025, the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) appointed J. David Joyner, President and Chief Executive Officer of the Company, to the additional role of Chair of the Board, effective January 1, 2026. Following the effective date of this appointment, Michael F. Mahoney will continue to serve as the Board’s Lead Independent Director and Roger N. Farah, who is currently serving as Executive Chair of the Board, will continue to serve on the Board.
Also on November 20, 2025, the Company issued a press release announcing the appointment of Mr. Joyner as Chair of the Board. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press Release, dated November 20, 2025. | |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: November 20, 2025 | CVS HEALTH CORPORATION | |||||
| By: | /s/ Kristina V. Fink | |||||
| Name: | Kristina V. Fink | |||||
| Title: | Senior Vice President, Chief Governance Officer and Corporate Secretary | |||||